EZH2 and small cell lung carcinoma: The addition of EZH2 inhibitors to cytotoxic chemotherapy prevented the emergence of acquired resistance and augmented chemotherapeutic efficacy in both chemosensitive and chemoresistant SCLC patient-derived models.